Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

Clinical and Diagnostic Laboratory Immunology logoLink to Clinical and Diagnostic Laboratory Immunology
. 1996 Jan;3(1):89–92. doi: 10.1128/cdli.3.1.89-92.1996

Production of agglutinating monoclonal antibody against antigen 8 specific for Cryptococcus neoformans serotype D.

R Ikeda 1, S Nishimura 1, A Nishikawa 1, T Shinoda 1
PMCID: PMC170253  PMID: 8770510

Abstract

A hybridoma (clone CRND-8) that produced agglutinating monoclonal antibody (MAb) against Cryptococcus neoformans serotype D was established by using a soluble capsular polysaccharide-keyhole limpet hemocyanin conjugate for immunization. The isotype was immunoglobulin M(kappa). Specificity was determined by cell slide agglutination and enzyme-linked immunosorbent assay (ELISA). In both tests, the MAb reacted to serotypes D and A-D but not to serotypes A, B, and C. Furthermore, the specificity of the MAb determined by ELISA was the same as that of polyclonal antibody factor serum (PAb factor) 8, which showed high-level reactivity with serotypes D and A-D. These results supported the deduced specificity of the PAb-based antigenic factor 8. A total of 15 isolates of serotypes D and A-D but no serotype A isolates reacted with the MAb in cell slide agglutination tests. CRND-8 MAb can be used in place of PAb factor 8 for serotyping C. neoformans isolates and for the analysis of the antigen 8 epitope.

Full Text

The Full Text of this article is available as a PDF (195.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Belay T., Cherniak R., Shinoda T. Specificity of Cryptococcus neoformans factor sera determined by enzyme-linked immunosorbent assay and dot enzyme assay. Infect Immun. 1993 Jul;61(7):2879–2885. doi: 10.1128/iai.61.7.2879-2885.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bhattacharjee A. K., Bennett J. E., Glaudemans C. P. Capsular polysaccharides of Cryptococcus neoformans. Rev Infect Dis. 1984 Sep-Oct;6(5):619–624. doi: 10.1093/clinids/6.5.619. [DOI] [PubMed] [Google Scholar]
  3. Casadevall A., Scharff M. D. The mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies. J Exp Med. 1991 Jul 1;174(1):151–160. doi: 10.1084/jem.174.1.151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chandler F. W. Pathology of the mycoses in patients with the acquired immunodeficiency syndrome (AIDS). Curr Top Med Mycol. 1985;1:1–23. doi: 10.1007/978-1-4613-9547-8_1. [DOI] [PubMed] [Google Scholar]
  5. Chang Y. C., Kwon-Chung K. J. Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol Cell Biol. 1994 Jul;14(7):4912–4919. doi: 10.1128/mcb.14.7.4912. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cherniak R., Sundstrom J. B. Polysaccharide antigens of the capsule of Cryptococcus neoformans. Infect Immun. 1994 May;62(5):1507–1512. doi: 10.1128/iai.62.5.1507-1512.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dromer F., Salamero J., Contrepois A., Carbon C., Yeni P. Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide. Infect Immun. 1987 Mar;55(3):742–748. doi: 10.1128/iai.55.3.742-748.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Eckert T. F., Kozel T. R. Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide. Infect Immun. 1987 Aug;55(8):1895–1899. doi: 10.1128/iai.55.8.1895-1899.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Furuya Y., Inoue M., Yoshihara N. Use of monoclonal antibodies in the assay of hepatitis B core antigen and antibody. Jpn J Med Sci Biol. 1984 Aug;37(4):151–159. doi: 10.7883/yoken1952.37.151. [DOI] [PubMed] [Google Scholar]
  10. Ikeda R., Matsuyama H., Nishikawa A., Shinoda T., Fukazawa Y. Comparison of serological and chemical characteristics of capsular polysaccharides of Cryptococcus neoformans var. neoformans serotype A and Cryptococcus albidus var. albidus. Microbiol Immunol. 1991;35(2):125–138. doi: 10.1111/j.1348-0421.1991.tb01540.x. [DOI] [PubMed] [Google Scholar]
  11. Ikeda R., Shinoda T., Fukazawa Y., Kaufman L. Antigenic characterization of Cryptococcus neoformans serotypes and its application to serotyping of clinical isolates. J Clin Microbiol. 1982 Jul;16(1):22–29. doi: 10.1128/jcm.16.1.22-29.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Jacobson E. S., Tingler M. J. Strains of Cryptococcus neoformans with defined capsular phenotypes. J Med Vet Mycol. 1994;32(5):401–404. [PubMed] [Google Scholar]
  13. Kabasawa K., Itagaki H., Ikeda R., Shinoda T., Kagaya K., Fukazawa Y. Evaluation of a new method for identification of Cryptococcus neoformans which uses serologic tests aided by selected biological tests. J Clin Microbiol. 1991 Dec;29(12):2873–2876. doi: 10.1128/jcm.29.12.2873-2876.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kozel T. R. Antigenic structure of Cryptococcus neoformans capsular polysaccharides. Immunol Ser. 1989;47:63–86. [PubMed] [Google Scholar]
  15. Kozel T. R., Cazin J., Jr Immune response to Cryptococcus neoformans soluble polysaccharide. I. Serological assay for antigen and antibody. Infect Immun. 1972 Jan;5(1):35–41. doi: 10.1128/iai.5.1.35-41.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kwon-Chung K. J., Bennett J. E. Epidemiologic differences between the two varieties of Cryptococcus neoformans. Am J Epidemiol. 1984 Jul;120(1):123–130. doi: 10.1093/oxfordjournals.aje.a113861. [DOI] [PubMed] [Google Scholar]
  17. Kwon-Chung K. J., Kozel T. R., Edman J. C., Polacheck I., Ellis D., Shinoda T., Dromer F. Recent advances in biology and immunology of Cryptococcus neoformans. J Med Vet Mycol. 1992;30 (Suppl 1):133–142. [PubMed] [Google Scholar]
  18. Murphy J. W., Cozad G. C. Immunological unresponsiveness induced by cryptococcal capsular polysaccharide assayed by the hemolytic plaque technique. Infect Immun. 1972 Jun;5(6):896–901. doi: 10.1128/iai.5.6.896-901.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Naka W., Masuda M., Konohana A., Shinoda T., Nishikawa T. Primary cutaneous cryptococcosis and Cryptococcus neoformans serotype D. Clin Exp Dermatol. 1995 May;20(3):221–225. doi: 10.1111/j.1365-2230.1995.tb01306.x. [DOI] [PubMed] [Google Scholar]
  20. White C. W., Cherniak R., Jacobson E. S. Side group addition by xylosyltransferase and glucuronyltransferase in biosynthesis of capsular polysaccharide in Cryptococcus neoformans. J Med Vet Mycol. 1990;28(4):289–301. doi: 10.1080/02681219080000381. [DOI] [PubMed] [Google Scholar]
  21. Wilson D. E., Bennett J. E., Bailey J. W. Serologic grouping of Cryptococcus neoformans. Proc Soc Exp Biol Med. 1968 Mar;127(3):820–823. doi: 10.3181/00379727-127-32812. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Diagnostic Laboratory Immunology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES